CWM
OVID icon

CIBC World Markets’s Ovid Therapeutics OVID Stock Holding History

CIBC World Markets’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,068
Closed -$4.08K – 1826
2025
Q1 		$4.08K Buy
+13,068
New +$8.04K ﹤0.01% 1839

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

CIBC World Markets's OVID Position: Q2 2025 in Review

CIBC World Markets sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 13,068 shares — an estimated $4.08K sold.

CIBC World Markets first reported a position in OVID in Q1 2025 and held it in 1 quarter. The position peaked at $4.08K in Q1 2025. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • CIBC World Markets reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CIBC World Markets sold 13,068 Ovid Therapeutics shares in Q2 2025, an estimated $4.08K.
  • CIBC World Markets first reported a position in Ovid Therapeutics in Q1 2025 and held it in 1 quarter.
  • CIBC World Markets's Ovid Therapeutics position peaked at $4.08K in Q1 2025.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.